ArticlePloS one2026
Diagnostic value of antibody responses to Mycobacterium avium subsp. paratuberculosis-derived proteins PtpA and PtpB in rheumatoid arthritis.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Evidence suggests that Mycobacterium avium subspecies paratuberculosis (MAP) may contribute to autoimmune diseases such as rheumatoid arthritis (RA), partly through effector proteins-particularly the tyrosine phosphatases PtpA and PtpB-that modulate macrophage signaling and promote bacterial persistence. This study evaluated whether serum antibodies against these proteins serve as biomarkers of RA. Humoral responses to PtpA and PtpB were quantified in Mexican RA patients (n = 100) and healthy controls (n = 100) using in-house ELISAs. Associations with disease activity (DAS28), ROC performance, and logistic regression models were assessed. Results showed that anti-PtpB antibody levels were significantly higher in patients with RA than in healthy controls (median OD 0.185 vs. 0.080; p < 0.0001) and had moderate discriminative capacity (AUC = 0.762). Anti-PtpB reactivity increased with higher disease activity and showed a significant positive association with DAS28 (p < 0.05). In addition, there was a functional disability measured by HAQ (p < 0.001), as well as moderate correlations with erythrocyte sedimentation rate and rheumatoid factor. A combined logistic regression model integrating both antibodies markedly improved diagnostic accuracy (AUC = 0.934), achieving high sensitivity (90%) and specificity (89%). These findings suggest a potential association of MAP with RA immunopathogenesis and indicate that combined quantification of anti-PtpA and anti-PtpB antibodies captures complementary and non-redundant immunological information. This combined serological approach may enhance RA diagnosis and provide clinically relevant insights into disease activity and severity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.